GRACE :: Head/Neck Cancer

pd-l1

Denise Brock

Head and Neck Cancer Treatment Update: Pembrolizumab, Nivolumab and PD-L1 Markers

Share

Dr. Jared Weiss, University of North Carolina School of Medicine

Drs. Jared Weiss, Assistant Professor, Clinical Research Hematology/Oncology, University of North Carolina School of Medicine, and Josh Bauml, Assistant Professor of Medicine, Hospital of the University of Pennsylvania, join GRACE to discuss updates relating to pembrolizumab, nivolumab and PD-L1 markers for head and neck cancers.

Joshua Bauml, MD, University of Pennsylvania

  

 


 Please feel free to offer comments and raise questions in our Discussion Forums.


 

 


Ask Us, Q&A
Head/Neck Cancer Expert Content

Archives

Share

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share

Join the GRACE Faculty

Lung/Thoracic Cancer Blog
Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Share

Subscribe to the GRACEcast Podcast on iTunes

Share

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243